Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy

Haemophilia

Volumn 20, Issue 4, 2014, Pages

  Abbonizio, F ^a   Giampaolo, A ^a   Coppola, A ^b   Arcieri, R ^c   Hassan, H J ^a   Accorsi, Arianna ^d   Ettorre, Pietro Cosimo ^d   Giordano, Paola ^d   Rodorigo, Giuseppina ^d   Valdre, Lelia ^d   Notarangelo, Lucia ^d   Aru, Anna Brigida ^d   Cultrera, Dorina ^d   Iannaccaro, Piergiorgio ^d   Chiara, Biasoli ^d   Di Gregorio, Patrizia ^d   Rossi, Vincenza ^d   Testa, Sophie ^d   Serino, Maria Luisa ^d   Morfini, Massimo ^d   Molinari, Angelo Claudio ^d   Delios, G Grazia ^d   Ciabatta, Carlo ^d   Peyvandi, Flora ^d   Santagostino, Elena ^d   Marietta, Marco ^d   Di Minno, Giovanni ^d   Perricone, Corrado ^d   Schiavulli, Michele ^d   Rocino, Angiola ^d   Zanon, Ezio ^d   Gagliano, Fabio ^d   Siragusa, Sergio ^d   Tagliaferri, Annarita ^d   Rivolta, Gianna Franca ^d   Gamba, Gabriella ^d   Gresele, Paolo ^d   Oliovecchio, Emily ^d   Dragani, Alfredo ^d   Arbasi, Maria Cristina ^d   Macchi, Silvia ^d   Albertini, Patrizia ^d   Latella, Caterina ^d   D'Incà, Marco ^d   Luciani, Matteo ^e   De Cristofaro, Raimondo ^f   Mazzucconi, Maria Gabriella ^g   Santoro, Cristina ^g   Piseddu, Gavino ^d   Schiavoni, Mario ^d   Spagnuolo, Pasquale ^d   Schinco, Pier Carla ^d   Messina, Maria ^h   Rossetti, Gina ^d   Cristallo, Attilio Fabio ^d   Barillari, Giovanni ^d   Feola, Giulio ^d   Cesaro, Simone ^d   Bonetti, Elisa ^d   Gandini, Giorgio ⁱ   Castaman, Giancarlo ^d   Rodeghiero, Francesco ^d   more..

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Federation of Haemophiliac Associations   (Italy)

^d Napoli Federico II ^*

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f Roma Gemelli   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h Division of Pediatric Endocrinology   (Italy)

ⁱ UNIVERSITY OF VERONA   (Italy)

Author keywords

aPCC; Bypassing agents; Haemophilia A; Immune tolerance induction; Inhibitors; rFVIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; EMOCLOT; FANHDI; NEXGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 8; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; PROTHROMBIN COMPLEX CONCENTRATES; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CHILD; DISEASE SEVERITY; DRUG COST; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; ITALY; PRIORITY JOURNAL; QUESTIONNAIRE; REGISTER; VON WILLEBRAND DISEASE; COMPLICATION; ECONOMICS; FEMALE; HEALTH CARE COST; HEMORRHAGE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MALE; NEWBORN; PRESCHOOL CHILD; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; FACTOR VIII; FEMALE; HEALTH CARE COSTS; HEMOPHILIA A; HEMORRHAGE; HUMANS; IMMUNOSUPPRESSION; INFANT; INFANT, NEWBORN; ITALY; MALE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84904735742     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12456     Document Type: Article

References (42)

1. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
2. Witmer C, Young G. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol 2013; 4: 59-72.
3. Astermark J, Donfield SM, Gomperts ED et al. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood 2013; 121: 1446-54.
4. Gouw SC, van den Berg HM, Oldenburg J et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119: 2922-34.
5. Santagostino E, Mancuso ME, Rocino A et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-7.
6. Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-54.
7. Gouw SC, van den Berg HM, Fischer K et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood 2013; 121: 4046-55.
8. Goudemand J, Rothschild C, Demiguel V et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
9. Mancuso ME, Mannucci PM, Rocino A et al. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost 2012; 10: 781-90.
10. Iorio A, Halimeh S, Holzhauer S et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8: 1256-65.
11. Franchini M, Coppola A, Rocino A et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013; 39: 752-66.
12. Gouw SC, van der Bom JG, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
13. Gringeri A, Mantovani LG, Scalone L et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
14. Morfini M, Haya S, Tagariello G et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-12.
15. Di Minno MN, Di Minno G, Di Capua M et al. Cost of care of haemophilia with inhibitors. Haemophilia 2010; 16: e190-201.
16. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9: 418-35.
17. White GC 2nd, Rosendaal F, Aledort LM et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
18. Astermark J, Rocino A, Von Depka M et al. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors. Haemophilia 2007; 13: 38-45.
19. Gringeri A, Mannucci PM. Italian Association of Haemophilia Centres. Italian guidelines for the diagnosis and treatment of patients with haemophilia and inhibitors. Haemophilia 2005; 11: 611-19.
20. Collins PW, Chalmers E, Hart DP et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160: 153-70.
21. Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013; 39: 772-8.
22. DiMichele DM, Hoots WK, Pipe SW et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13: 1-22.
23. Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-28.
24. Rocino A, Santagostino E, Mancuso ME, Mannucci PM. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica 2006; 91: 558-61.
25. Gringeri A, Musso R, Mazzucconi MG et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.
26. Hay CR, DiMichele DM. International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
27. Di Minno G, Coppola A. Management of patients with long-term inhibitors: is immune tolerance an underestimated life-long solution? Haemophilia 2013; 19: 18-23.
28. Gringeri A, Fischer K, Karafoulidou A et al. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia 2011; 17: 630-5.
29. Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012; 38: 79-94.
30. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
31. Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011; 365: 1684-92.
32. Antunes SV, Tangada S, Stasyshyn O et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 2014; 20: 65-72.
33. Abbonizio F, Giampaolo A, Arcieri R et al. Registro Nazionale delle Coagulopatie Congenite. Rapporto 2011. Rapporti ISTISAN 2012; 12/55.
34. Giampaolo A, Abbonizio F, Puopolo M et al. Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy. Transfus Med 2011; 21: 280-4.
35. Iorio A, Oliovecchio E, Morfini M et al. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. Haemophilia 2008; 14: 444-53.
36. Darby SC, Keeling DM, Spooner RJ et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
37. Coppola A, Margaglione M, Santagostino E et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 2009; 7: 1809-15.
38. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
39. Santagostino E, Mannucci PM, Bianchi Bonomi A. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6: 1-10.
40. Franchini M, Coppola A, Rocino A et al. Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters. The 2013 AICE survey. Haemophilia 2014; 20: e128-35.
41. Coppola A, Tagliaferri A, Calizzani G et al. Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates. Blood Transfusion 2013; 11: 101-9.
42. Farrugia A, Cassar J, Kimber MC et al. Treatment for life for severe haemophilia A - A cost utility model for prophylaxis vs. on-demand treatment. Haemophilia 2013; 19: e228-38.